IGCAN Directory
login/create account
Donate
Dear IGCS Members,
We are pleased to announce that the Brazilian Gynecologic Oncology Group – EVA Group– has officially joined the International Gynecologic Cancer Society’s Strategic Alliance Partner Program.
Founded in 2013, EVA is a respected, mission-driven, nonprofit association dedicated to advancing gynecologic cancer care across Brazil through education, research, prevention, awareness and comprehensive patient support.
IGCS Milestone Reached – 10K Members!
By joining IGCS, EVA will bring over 700 new members into our global network, a milestone that is set to push IGCS membership past 10,000 for the first time. Instrumental to this partnership were EVA President, Dr. Andréa Paiva Gadêlha Guimarães; EVA 1st Vice President and current IGCS Board Member, Dr. Graziela Zibetti Dal Molin and Dr. Gustavo Guitmann, EVA’s Director of International Relations.
EVA President, Dr. Andréa Paiva Gadêlha Guimarães said “This partnership represents more than a formal collaboration; it reflects a shared commitment to scientific progress, capacity building, and the continuous improvement of patient-centered care. We look forward to developing collaborative projects, educational initiatives, and opportunities for mutual engagement that will contribute to the growth of our institutions and, most importantly, to the advancement of science.”
What EVA Brings & How Our Alliance Will Help
EVA unites Brazilian clinicians, allied professionals and patients around a shared mission: to fight gynecologic cancers through awareness, education, research, prevention, and patient support.
By joining IGCS, EVA gains access to our global network, educational resources, and international collaborations — supporting their efforts to address the cancer burden across Brazil. At the same time, IGCS benefits from EVA’s deep local expertise and leadership, and patient awareness programs, helping enrich our global perspective with the realities and needs of Brazilian women and healthcare providers.
IGCS President, Prof. Greta Dreyer, said “IGCS is made so much more powerful though the local expertise of regional societies and EVA’s dedication to holistic, equitable gynecologic cancer care aligns strongly with IGCS’ mission. This alliance fosters a meaningful two-way exchange, and we look forward to a strong and impactful collaboration. With Latin America a true priority for IGCS in 2026, this partnership represents an outstanding start.”
Dr. Graziela Zibetti Dal Molin, EVA 1st Vice President and current IGCS Board Member, said: “The partnership between EVA and IGCS represents a pivotal step in strengthening international collaboration across Latin America. It creates a unique opportunity to expand continuing medical education, training initiatives, and advocacy efforts, fostering meaningful exchange between Brazilian physicians and the global gynecologic oncology community, while also serving as an important milestone in extending this project to other Latin American countries.”
Why This Partnership Matters
In Brazil, gynecologic and breast cancers are among the most frequently diagnosed cancers in women. Cervical cancer remains a major burden, particularly in underserved regions, with many cases diagnosed at advanced stages — a reality tied to unequal access to screening, diagnostics and timely care. Challenges remain in many parts of Brazil: uneven distribution of specialized healthcare resources, limited access to advanced treatments, and structural inequities that disproportionately affect women in low-resource regions.
Because of these realities — the high burden of gynecologic cancers, regional disparities in care, and urgent need for better education, prevention, and treatment access — the work of EVA is especially vital.
Dr. Gustavo Guitmann, EVA’s Director of International Relations shared his sentiments about the partnership: “Seeing this collaboration come to fruition reinforces my belief in the power of shared vision, international cooperation, and collective commitment to advancing gynecologic oncology on a global scale. This alliance represents not only an institutional milestone, but also a meaningful step forward that will bring lasting benefits to our professionals, our organizations, and, most importantly, to patients worldwide.”
We are truly excited about the future of this partnership and confident that together we will achieve impactful and enduring results.
Sincerely,
Mary Eiken, MS
IGCS CEO